Cervical mucus antibodies against human papillomavirus type 16, 18, and 33 capsids in relation to presence of viral DNA

被引:39
作者
Wang, ZH
Hansson, BG
Forslund, O
Dillner, L
Sapp, M
Schiller, JT
Bjerre, B
Dillner, J
机构
[1] KAROLINSKA INST, CTR MICROBIOL & TUMOR BIOL, S-17177 STOCKHOLM, SWEDEN
[2] LUND UNIV, MALMO UNIV HOSP, DEPT MED MICROBIOL, MALMO, SWEDEN
[3] LUND UNIV, MALMO UNIV HOSP, DEPT OBSTET & GYNECOL, MALMO, SWEDEN
[4] UNIV MAINZ, DEPT MED MICROBIOL, MAINZ, GERMANY
[5] NIH, CELLULAR ONCOL LAB, BETHESDA, MD 20892 USA
关键词
D O I
10.1128/JCM.34.12.3056-3062.1996
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
To investigate whether cervical mucus antibodies against human papillomavirus (HPV) capsids are associated with the detection of HPV DNA or HPV-related cytological diagnoses, 611 samples of cervical secretions from 359 women referred to a colposcopy clinic were tested by an enzyme-linked immunosorbent assay for the presence of immunoglobulin A (IgA) antibodies against HPV capsids of HPV type 16, 18, or 33 and for the presence of cervical HPV DNA by PCR. Among subjects with at least one cervical sample positive for HPV type 16 (HPV-16) DNA, 28.1% also had at least one HPV-16 IgA-positive cervical sample (odds ratio [OR] = 2.9; P = 0.0003). IgA to HPV-18 was also more common among HPV-18 DNA-positive subjects (OR = 3.1; P = 0.0325) and IgA to HPV-33 was more common among HPV-33 DNA-positive subjects (OR = 4.2; P = 0.0023). Cervical IgA antibodies to HPV-16 were also more common among patients with cervical intraepithelial neoplasia, particularly among patients with cervical intraepithelial neoplasia grade I (P < 0.0005). The data indicate that an HPV type-restricted IgA antibody response against HPV capsids is detectable in cervical mucus and is associated with a concomitant cervical HPV infection.
引用
收藏
页码:3056 / 3062
页数:7
相关论文
共 25 条
  • [1] Comparison of development of serum antibodies to HPV16 and HPV33 and acquisition of cervical HPV DNA among sexually experienced and virginal young girls - A longitudinal cohort study
    AnderssonEllstrom, A
    Dillner, J
    Hagmar, B
    Schiller, J
    Sapp, M
    Forssman, L
    Milsom, I
    [J]. SEXUALLY TRANSMITTED DISEASES, 1996, 23 (03) : 234 - 238
  • [2] BISTOLETTI P, 1988, CANCER-AM CANCER SOC, V62, P2056, DOI 10.1002/1097-0142(19881101)62:9<2056::AID-CNCR2820620931>3.0.CO
  • [3] 2-K
  • [4] IMMUNIZATION WITH VIRUS-LIKE PARTICLES FROM COTTONTAIL RABBIT PAPILLOMAVIRUS (CRPV) CAN PROTECT AGAINST EXPERIMENTAL CRPV INFECTION
    BREITBURD, F
    KIRNBAUER, R
    HUBBERT, NL
    NONNENMACHER, B
    TRINDINHDESMARQUET, C
    ORTH, G
    SCHILLER, JT
    LOWY, DR
    [J]. JOURNAL OF VIROLOGY, 1995, 69 (06) : 3959 - 3963
  • [5] DIVERGENT HUMAN PAPILLOMAVIRUS TYPE-16 VARIANTS ARE SEROLOGICALLY CROSS-REACTIVE
    CHENG, G
    ICENOGLE, JP
    KIRNBAUER, R
    HUBBERT, NL
    STLOUIS, ME
    HAN, CL
    SVARE, EI
    KJAER, SK
    LOWY, DR
    SCHILLER, JT
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1995, 172 (06) : 1584 - 1587
  • [6] DETECTION OF HUMAN SERUM ANTIBODIES THAT NEUTRALIZE INFECTIOUS HUMAN PAPILLOMAVIRUS TYPE-11 VIRIONS
    CHRISTENSEN, ND
    KREIDER, JW
    SHAH, KV
    RANDO, RF
    [J]. JOURNAL OF GENERAL VIROLOGY, 1992, 73 : 1261 - 1267
  • [7] CHUA KL, IN PRESS INT J CANC
  • [8] DILLNER J, 1995, CANCER J - FRANCE, V8, P264
  • [9] Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior
    Dillner, J
    Kallings, I
    Brihmer, C
    Sikstrom, P
    Koskela, P
    Lehtinen, M
    Schiller, JT
    Sapp, M
    Mardh, PA
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1996, 173 (06) : 1394 - 1398
  • [10] ANTIBODIES AGAINST PAPILLOMAVIRUS ANTIGENS IN CERVICAL SECRETIONS FROM CONDYLOMA PATIENTS
    DILLNER, L
    FREDRIKSSON, A
    PERSSON, E
    FORSLUND, O
    HANSSON, BG
    DILLNER, J
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1993, 31 (02) : 192 - 197